ALIM - Alimera's partner files for approval of eye implant therapy Iluvien in Switzerland

• Alimera Sciences ( NASDAQ: ALIM ) said its distribution partner Horus Pharma through its Swiss affiliate Horus Pharma Suisse filed a marketing authorization application (MAA) in Switzerland  for Iluvien to treat diabetic macular edema (DME).
• The Swiss application for consistent with the U.S. approved labeling for Iluvien (fluocinolone acetonide intravitreal implant) to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
• DME is a condition which can occur in people with diabetes, wherein high blood sugar can damage the blood vessels in the retina of the eye. Tiny bulges form in the blood vessels, leaking fluid in the retina. This fluid can cause swelling in a part of the retina called the macula.
• "Horus Pharma has been a close partner for us, with proven success selling ILUVIEN in other European markets, and has worked very quickly with our team to develop this dossier," said Alimera  President and CEO Rick Eiswirth.
• Iluvien is a fluocinolone acetonide intravitreal implant, which is injected in the back of the eye.

For further details see: